Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Argenx has entered an agreement to acquire Forte Biosciences for $2.2 billion. The deal allows Argenx to add the first-in-class anti-CD122 antibody, known as FB102, to its existing immunology portfolio.
Coverage from the Wall Street Journal, Endpoints News, and Fierce Biotech emphasizes the strategic push into autoimmune treatments. FirstWord Pharma and GlobeNewswire highlight the integration of Forte's assets into the Argenx pipeline.
Future developments center on the progression of FB102, which Fierce Biotech identifies as a phase 2-stage drug targeting vitiligo.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6m ago.
Quick answers
How much is Argenx paying for Forte Biosciences?
The acquisition price is $2.2 billion.
What specific asset is Argenx acquiring?
Argenx is acquiring FB102, a first-in-class anti-CD122 antibody.
What is the current development stage of the vitiligo drug?
According to Fierce Biotech, the drug is currently in phase 2.
Coverage (6)
- Argenx to acquire Forte Biosciences for $2.2B Axios · 12h ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 12h ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 12h ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 12h ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 12h ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 12h ago
Topics
Related trends
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.
Breakdown of immune cells' interaction is key driver in aging, study finds
New research identifies the breakdown of immune cell communication as a primary driver of systemic aging.
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
Biologists pinpoint how common virus triggers multiple sclerosis
New biological research identifies specific Epstein-Barr virus components linked to the development of multiple sclerosis.
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.